For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $1.25 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.27, up 1.60%. In other words, the price has increased by $1.60 from its previous closing price. On the day, 1.27 million shares were traded. FATE stock price reached its highest trading level at $1.3 during the session, while it also had its lowest trading level at $1.24.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.29 and its Current Ratio is at 8.29. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.25.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 10 ’25 when Bressi Jerome Charles sold 5,980 shares for $1.55 per share. The transaction valued at 9,269 led to the insider holds 270,203 shares of the business.
TAHL CINDY sold 5,654 shares of FATE for $8,764 on Jan 10 ’25. The insider now owns 336,707 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, Valamehr Bahram, who serves as the President and CEO of the company, sold 8,705 shares for $1.54 each. As a result, the insider received 13,406 and left with 349,364 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 144645376 and an Enterprise Value of -53296196. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.75 while its Price-to-Book (P/B) ratio in mrq is 0.40. Its current Enterprise Value per Revenue stands at -3.963 whereas that against EBITDA is 0.324.
Stock Price History:
The Beta on a monthly basis for FATE is 2.05, which has changed by -0.73093224 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -38.76%, while the 200-Day Moving Average is calculated to be -63.13%.
Shares Statistics:
The stock has traded on average 3.20M shares per day over the past 3-months and 2800610 shares per day over the last 10 days, according to various share statistics. A total of 113.88M shares are outstanding, with a floating share count of 97.84M. Insiders hold about 13.97% of the company’s shares, while institutions hold 87.37% stake in the company. Shares short for FATE as of 1735603200 were 11195194 with a Short Ratio of 3.50, compared to 1732838400 on 11348453. Therefore, it implies a Short% of Shares Outstanding of 11195194 and a Short% of Float of 11.2799995.
